BMS Reports Long-Term Efficacy of Melanoma Combo Therapy Opdivo-Yervoy
Significant Long-Term Results for Melanoma Treatment
Bristol Myers Squibb (BMS) presented notable findings at the European Society for Medical Oncology (ESMO) Congress regarding the Phase III results of its already approved Opdivo-Yervoy combination treatment for melanoma. More than 10 years later, the survival rate has been reported to be 43%, providing vital hope for patients previously facing bleak prognoses.
Impressive Overall Survival Rates Compared
The long-term data revealed that patients receiving the Opdivo-Yervoy combination achieved a median overall survival of 71.9 months, significantly higher compared to Opdivo alone at 36.9 months and Yervoy at 19.9 months. According to BMS, this marks the longest reported median overall survival in a Phase III advanced melanoma trial.
Implications for Patients with Advanced Melanoma
- In this trial, 64% of patients on the combination therapy did not need any further systemic therapy at 10 years.
- Just over a decade ago, patients faced a prognosis of only months to live with advanced melanoma.
- BMS’s vice president Dana Walker emphasized the transformative impact of this dual immunotherapy.
This report highlights the hope and advancements being made in the fight against melanoma.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.